Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019· 2019 · 92 citations
2. Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018· 2019 · 36 citations
3. Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans· 2017 · 26 citations
4. Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D· 2020 · 28 citations
5. Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D· 2019 · 52 citations